In addition, DIO3OS may be a novel immunotherapeutic target for osteosarcoma by suppressing immune checkpoints (CD200 and TNFRSF25) and is a novel diagnostic biomarker to distinguish osteosarcoma from multiple other subtypes of sarcoma. Here, CD200 is linked to sarcoma.